
Please try another search
PARIS (Reuters) - French drugmaker Sanofi (NASDAQ:SNY) said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio (NASDAQ:TBIO), as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.
In a statement that confirmed an exclusive report by Reuters, Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio.
The boards of both companies had approved the deal, the firm added.
"Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology to develop both best-in-class vaccines and therapeutics," Chief Executive Paul Hudson (NYSE:HUD) said.
By Victoria Waldersee BERLIN (Reuters) - BMW is exploring new investments in solar, geothermal and hydrogen energy to lower its dependence on natural gas, the carmaker's...
By Rich McKay ATLANTA (Reuters) - Health authorities said they may have found a third case of the monkeypox virus in the United States and are running tests on a patient in South...
By Sam Nussey TOKYO (Reuters) - Space is a key area of cooperation for Japan with the United States, its closest ally, amid heightened tensions with an increasingly assertive...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.